-
Analyst Expectations For Amgen's Future
28 Jan 2025 13:29 GMT
… date on Amgen analyst ratings.
About Amgen
Amgen is a … for inflammatory diseases. Amgen introduced its first cancer … biosimilar portfolio.
Financial Insights: Amgen
Market Capitalization: Positioned above … capital.
Return on Assets (ROA): Amgen's ROA …
-
JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen
15 Jan 2025 13:35 GMT
… and when we find transformative assets that are either complementary to … the game in important diseases.”
Amgen Doubles Down on MariTide Despite …
Speaking to reporters on Tuesday, Amgen officials defended the Phase II …
-
Amgen: Blockbusters, Emerging Therapies, And Investment Potential
06 Jan 2025 02:53 GMT
Summary
Amgen's strong product … on BLINCYTO, but promising pipeline assets are expected to offset these … iStock via Getty Images Thesis Amgen Inc. (NASDAQ:AMGN) is a biotechnology powerhouse … position in the shares of AMGN either through stock ownership, …
-
Demystifying Amgen: Insights From 13 Analyst Reviews
10 Dec 2024 13:25 GMT
… on Amgen analyst ratings.
Get to Know Amgen Better
Amgen … for inflammatory diseases. Amgen introduced its first cancer … portfolio.
Financial Insights: Amgen
Market Capitalization: Positioned above … effective utilization of assets.
Debt Management: Amgen's …
-
Amgen's Weight-loss Drug Fails to Impress in Study; Shares Plunge
26 Nov 2024 14:17 GMT
… P. Morgan analyst Chris Schott.
Amgen said nausea and vomiting events … ($1.26 billion) in assets.
Still, Amgen is betting on the drug … potentially 12 or fewer," Amgen's chief scientific … second gut hormone called GIP.
Amgen's MariTide, while …
-
US close: Dow falls for fourth day, but Nvidia lifts Nasdaq
19 Nov 2024 22:45 GMT
… investors rushed for safe-haven assets, rattled by escalating tensions between … providing a lift on the Nasdaq, jumping nearly 5% ahead of … ) $417.79 0.49%
Amgen Inc. (AMGN) $279.95 0.43%
Salesforce … . (CDNS) $299.70 1.83%
Nasdaq 100 - Fallers
Qurate Retail …
-
What’s Happening With Amgen Stock?
13 Nov 2024 16:07 GMT
… /LightRocket via Getty Images
Amgen stock (NASDAQ: AMGN) saw a 7% fall … the dosage for Amgen. Barring the recent decline, AMGN stock has fared … a percentage of assets of around 10%, we think Amgen looks reasonably …
-
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink
13 Nov 2024 17:02 GMT
… Bristol Myers Squibb, Merck, Amgen, Novartis and AstraZeneca are staring … acquirers of earlier-stage assets.”
LOEs on the horizon … across all therapeutic areas.”
Amgen faces the next greatest exposure … decade
While BMS, Merck, Amgen, Novartis and AZ will …
-
Amgen Inc. (AMGN): Pioneering Healthcare Innovations in Obesity Treatment
14 Aug 2024 14:41 GMT
… drug developed by the company.
Amgen Inc. (NASDAQ:AMGN)
Number of Hedge Fund … total assets and $10.9 billion in cash means that Amgen Inc. (NASDAQ:AMGN … from Amgen Inc. (NASDAQ:AMGN) is years away.
Here’s what Amgen Inc. (NASDAQ:AMGN)’s …
-
Amgen Whets Investors’ Appetites for MariTide Obesity Data by End of Year
31 Oct 2024 13:02 GMT
… .
By contrast, Amgen’s top-selling assets Tepezza and Prolia … limited details” for the Amgen’s highly anticipated obesity candidate … portfolio, pointing out that Amgen provided only “incremental points” … more frustrated,” given that Amgen’s business will be …